Skip to main content
Premium Trial:

Request an Annual Quote

Intellimedix to use BGI Tech Sequencing Service for Enhanced Accelerated Exome

NEW YORK (GenomeWeb) – Intellimedix said today that it is collaborating with BGI Tech to offer an exome sequencing service on Thermo Fisher's Ion Proton at 100x coverage.

The service will use Intellimedix's interpretative software, Prognostix, developed by Jeffrey Skolnick, director of the Center for the Study of Systems Biology at the Georgia Institute of Technology and a scientific advisor to Intellimedix.

Prognostix incorporates 3D protein structure to make more precise predictions about a DNA mutation's possible pathogenicity. According to Intellimedix, it has a three-fold lower rate of false positives.

The service will have a 10-day turnaround time — seven for sequencing and three for full interpretation and annotation — as opposed to the industry norm of eight weeks, according to Intellimedix.

"Our joint effort will redefine customer service in the exome research marketplace, setting a new standard across the genomic sequencing and interpretation industry," Skolnick said in a statement.

"Coupling our exome service with Intellimedix's proprietary algorithms will provide researchers rapid, in-depth sequencing with enhanced annotation and interpretation," BGI CEO Yingrui Li said in the statement.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.